Hemoglobinopathies Market Is Estimated To Grow Up, Due To Rising Prevalence Of Conditions Such As Sickle Cell Disease (SCD) And Thalassemia

 

 

 

Hemoglobinopathies Industry Overview

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

 

Hemoglobinopathies Market Segmentation

Grand View Research has segmented the global hemoglobinopathies market on the basis of type, diagnosis, therapy, and region:

 

Based on the Type Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.

• The sickle cell disease segment held the largest share of 56.6% in 2020 and is expected to grow at the fastest rate during the forecast period.
• This is attributed to growing initiatives by biopharmaceutical companies and nonprofit organizations focused on improving access to SCD treatment. Furthermore, sickle cell disease affects around 300,000 newborns annually. An estimated 10% to 40% of the individuals in many African countries are carriers of sickle cell gene, which has resulted in a prevalence of around 2% in these countries.
• The thalassemia segment is further sub-segmented into alpha-thalassemia and beta-thalassemia. Globally, 5% of the total population are carriers of alpha-thalassemia and around 1.5% of the population have beta-thalassemia traits. India has the maximum number of thalassemia carriers in the world.

 

Based on the Diagnosis Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.

• The sickle cell disease diagnosis segment dominated the market and accounted for more than 50.0% share in 2020 owing to high diagnostic rates in North America and Europe.
• Blood tests are most widely used for the diagnosis of SCD in patients. Moreover, the introduction of newborn baby screening programs for sickle cell disease in countries, such as the U.S., France, and Italy, will drive the segment at the fastest rate.
• The thalassemia diagnosis segment is estimated to grow at a significant rate over the forecast period. The introduction of technologically advanced, rapid, and user-friendly diagnostic tests is driving the segment.

 

Based on the Therapy Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.

• The sickle cell disease segment held the largest revenue share of 59.4% in 2020. Extensive research has been carried out to develop novel therapies for treating the disorder, which is contributing to the segment growth.
• Gene therapy has emerged as a promising treatment option for managing the disorder as it targets the underlying genetic cause of the condition through one-time administration and reduces the need for patients to undertake blood transfusions.
• Blood transfusion is considered to be the first line of treatment for hemoglobin disorders. The frequency of blood transfusion is higher in thalassemia cases as compared to other hemoglobinopathies. The transfusion is done every 3 to 4 weeks to help maintain the normal level of blood components.
• Bone marrow transplant (BMT) therapy is expected to expand at a significant growth rate over the forecast period. BMT is often used when blood transfusion and other therapies fail. BMT is reported to be effective when performed in the early stages of disease progression. 

 

Hemoglobinopathies Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Market players are taking up various initiatives, such as mergers & acquisitions, partnerships, collaborations, and extensive R&D, in order to gain a greater share in the market.

Some prominent players in the global hemoglobinopathies market include

• Sangamo Therapeutics, Inc.
• Global Blood Therapeutics, Inc.
• bluebird bio, Inc.
• Emmaus Life Sciences Inc.
• Pfizer, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Bioverativ Inc.
• Gamida Cell

 

Order a free sample PDF of the Hemoglobinopathies Market Intelligence Study, published by Grand View Research.

 

 

Intravenous Immunoglobulin Market To Rise Up, Due To Increasing Adoption Of Intravenous Immunoglobulin (IVIG) Treatments And Rising Use Of Off-Label Indications

  

 

 

Intravenous Immunoglobulin Industry Overview

 

The global intravenous immunoglobulin market size is expected to reach USD 21.1 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.

 

Intravenous Immunoglobulin Market Segmentation

Grand View Research has segmented the global intravenous immunoglobulin market on the basis of application, distribution channel, and region:

 

Based on the Application Insights, the market is segmented into Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome, Others.

• In 2021, immunodeficiency diseases dominated the market with a revenue share of over 20.0% owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. 
• The chronic inflammatory demyelinating polyneuropathy segment held the second-largest share in 2021. It is usually found in patients with diabetes mellitus. The treatment of CIDP involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods.
• Hypogammaglobulinemia accounted for the third-largest revenue share in 2021. This can be attributed to the increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).
• The Kawasaki disease segment is expected to witness lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years.

 

Based on the Distribution Channel Insights, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, Others.

• The hospital pharmacy segment dominated the market with a revenue share of over 55.0% in 2021 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies.
• Moreover, the growing incidence of primary immune deficiencies, hepatitis C, and other diseases has resulted in an increment in the number of hospitalizations worldwide, expanding the customer preference for hospital pharmacies.
• Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies.
• The specialty pharmacy segment is anticipated to grow significantly during the forecast period as specialty pharmacies enable easy treatment at home. Specialty drugs are an important and dynamic part of the pharmacy

 

Intravenous Immunoglobulin Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

This industry is witnessing a significant boost owing to the growing number of FDA approvals. Owing to this, a number of local and international players are investing in the IVIG business. Market players are adopting various strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a greater share by increasing their market penetration. 

 

Some prominent players in the global intravenous immunoglobulin market include

• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc.

 

Order a free sample PDF of the Intravenous Immunoglobulin Market Intelligence Study, published by Grand View Research.

 

Astaxanthin Market Is Expected To Rise, As Of Government Initiatives To Increase The Manufacturing Capacity

  

 

 

Astaxanthin Industry Overview

 

The global astaxanthin market size is expected to reach USD 4.75 billion by 2028, registering a CAGR of 16.8%, according to a new report by Grand View Research, Inc. Increasing adoption of dietary supplements, growing awareness among people regarding healthy lifestyle, and government initiatives to increase the manufacturing capacity are anticipated to boost the market growth. For instance, in May 2019, Algalíf Iceland ehf. received financial aid from EU’s SME Instrument program and Icelandic Centre for Research’s Technology Development Fund to expand its manufacturing capacities by adding spray dryers.

 

Astaxanthin Market Segmentation

Grand View Research has segmented the global astaxanthin market on the basis of source, product, application, and region:

 

Based on the Product Insights, the market is segmented into Dried Algae Meal or Biomass, Oil, Softgel, Liquid, Others.

• The dried algae meal or biomass segment dominated the global market in 2020 with a revenue share of over 25% and is anticipated to maintain its dominance over the forecast period.
• The use of biomass for the production of other formulations, the requirement of less downstream processing, high usage as animal feed, and easy bulk production are some key factors driving the segment growth. Moreover, biomass has a variety of products ranging from 1 to 5% of astaxanthin-containing products, which increase the usage of biomass in different end-use industries.
• The softgels segment is anticipated to exhibit the fastest growth rate of 17.4% during the forecast period owing to increased use in nutraceuticals and significant growth of the nutraceuticals industry.

 

Based on the Source Insights, the market is segmented into Natural, Synthetic.

• The natural source segment dominated the market in 2020 and is estimated to witness the fastest CAGR of 19.3% during the forecast period. Wide-scale availability, increased demand for natural food supplements, and higher efficacy compared to synthetic sources are key factors driving the segment growth.
• Synthetic astaxanthin is also expected to grow at a double-digit growth rate over the forecast period owing to increased demand from the aquaculture industry and availability of safe & approved products, such as Cardax, Inc.’s ZanthoSyn as an anti-inflammatory.

 

Based on the Application Insights, the market is segmented into Nutraceuticals, Cosmetics, Aquaculture &Animal Feed, Food, Others.

• The aquaculture and animal feed segment dominated the market in 2020 with a revenue share of over 47% and is anticipated to grow at a steady CAGR over the forecast period, owing to its extensive use as a feed additive.
• Moreover, a rise in the adoption of astaxanthin in the aquaculture industry for improving the quality of seafood is contributing to the segment’s significant share in the market. Key market players are developing the product containing astaxanthin as animal feed having medical benefits.
• The nutraceuticals segment is estimated to witness the fastest growth over the forecast period owing to the superior antioxidant properties of astaxanthin as compared to other food supplements, easier availability, and a wider range of applications in the nutraceuticals industry. 

 

Astaxanthin Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Key players are contributing to market growth by adopting various strategies, such as geographical expansion, to gain a higher market share. In addition, companies are focusing on gaining market approvals for innovative products to help in the management of different health conditions.

 

Some prominent players in the global astaxanthin market include

• CO2 GRO Inc. (BlueOceanNutraSciences)
• FENCHEM
• ENEOS Corporation (JXTG Nippon Oil & Energy Corporation)
• E.I.D. – Parry (India) Limited
• MicroA
• NextFerm
• Algalif Iceland ehf
• ALGAMO

 

Order a free sample PDF of the Astaxanthin Market Intelligence Study, published by Grand View Research.

 

Veterinary Equipment And Disposables Market To Strike CAGR Of 8.8% From 2022 To 2030

 

 

Veterinary Equipment And Disposables Industry Overview

 

The global veterinary equipment and disposables market size is expected to reach USD 4.4 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.8% from 2022 to 2030. Increasing pet health expenditure and growing concern among pet owners are driving the market. Advancement in veterinary equipment and growing initiatives by the industry players are boosting the growth. Companies are investing in the expansion of their manufacturing facilities, which is expected to positively influence the revenue over the forecast period. For instance, in June 2021, Veterinary Instrumentation (VI), announced an expansion in the U.S. market. With this expansion, VI is going to bring the support of the expert team to veterinarians and more than 4,000 professional veterinary instruments in the U.S. This initiative is expected to boost the company’s growth, as it allows brand development in North America.

 

Veterinary Equipment And Disposables Market Segmentation

Grand View Research has segmented the global veterinary equipment and disposables market on the basis of product, animal type, end use, and region:

 

Based on the Product Insights, the market is segmented into Critical Care Consumables, Anesthesia Equipment, Fluid Management Equipment, Temperature Management Equipment, Rescue & Resuscitation Equipment, Research Equipment, Patient Monitoring Equipment.

• The critical care consumables segment dominated the market for veterinary equipment and disposables and held the largest revenue share of over 33.0% in 2021.
• The growth can be attributed to increasing usage of the consumables for various applications such as wound management, airway management, gastroenterology, reproduction, and others. Continuous development and new product launches by the industry players are bolstering the growth.
• The rescue and resuscitation equipment segment is expected to show the fastest growth over the forecast period. Managing cardiopulmonary arrest requires quick patient assessment, with immediate implementation of Cardiopulmonary Resuscitation (CPR) in cats and dogs.
• Rescue and resuscitation equipment is divided into resuscitation bags and oxygen masks. The resuscitation bags segment accounted for the largest market share of over 50.0% under the rescue and resuscitation equipment segment in 2021, owing to their immediate effectiveness in saving lives. 

 

Based on the Animal Type Insights, the market is segmented into Companion Animal, Livestock Animal.

• The companion animals segment dominated the market for veterinary equipment and disposables and accounted for the largest revenue share of over 64.0% in 2021. Growth in the companion animal population, rising emphasis on pet care, and wellness by pet owners are contributing to the growth of this segment.
• The dogs segment held the largest market share of the companion animals segment in 2021. The dominant share captured by this is a consequence of the increased number of surgeries. The growing incidence of chronic diseases in dogs is one of the major drivers for the market.
• The growing trend of pet adoption is anticipated to accelerate the growth of the market for veterinary equipment and disposables. In the last 30 years, pet ownership has increased from 56.0% to 67.0% in all households and nearly 85.0 million households have a pet, according to American Pet Products Association.
• The growing demand for better treatment and diagnostics, increasing activities in animal husbandry, and growing awareness about the care of livestock animals are some of the key drivers for livestock animal segment growth. Growing initiatives such as stray animal rescue programs and increasing usage of rescue and resuscitation equipment are boosting the revenue.

 

Based on the End-use Insights, the market is segmented into Veterinary Hospitals/Clinics, Research Institutes.

• The veterinary hospitals/clinics segment dominated the market for veterinary equipment and disposables and accounted for a revenue share of around over 82.0% in 2021. The growth can be attributed to the availability of a wide range of treatment options in veterinary hospitals and veterinary clinics.
• Various government animal welfare organizations have issued guidelines for safety practices and standards to be implemented in hospitals, which has broadened the scope for segment growth over the past few years.
• The research institutes segment is expected to show lucrative growth over the forecast period. Better critical care treatment options for small animals have triggered the demand for research activities which is expected to drive the segment over the forecast period.
• The COVID-19 pandemic has intensified research activities, while veterinary institutes are also focused on finding a solution for African swine fever and Highly Pathogenic Avian Influenza (HPAI).

 

Veterinary Equipment And Disposables Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market players are constantly involved in strategic initiatives such as new product launches, regional expansion, and mergers and acquisitions to gain deeper penetration.

 

Some prominent players in the global veterinary equipment and disposables market include

• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Smiths Medical, Inc.
• Nonin Medical, Inc.
• Digicare Biomedical
• Covetrus, Inc.
• B. Braun Melsungen AG
• DRE Veterinary
• Vetland Medical Sales and Services
• Midmark Corporation
• Jorgensen Labs
• Grady Medical

 

Order a free sample PDF of the Veterinary Equipment And Disposables Market Intelligence Study, published by Grand View Research.

Personal Mobility Devices Market Is Extrapolated To Rise, Due To Increasing Number Of Accidents And Trauma Cases

 

 

 

Personal Mobility Devices Industry Overview

 

The global personal mobility devices market size is expected to reach USD 29.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.3% from 2022 to 2030. The increasing R&D investments for the development of advanced mobility products and government initiatives to support reimbursement policies are some of the key factors boosting the market growth. The rising geriatric population and prevalence of chronic diseases, such as Parkinson’s, arthritis, and Alzheimer’s, are expected to drive the market over the forecast period.

 

The market is disrupted due to the COVID-19 pandemic during the second quarter of 2020 which affected the shipping and transportation of the devices. The decreasing production of these devices due to the pandemic has severely affected the industry's growth. The prices of wheelchairs and scooters have also been affected due to a decrease in the demand for the product. The market is likely to grow at a lucrative rate after the second half of 2020 as there is the ease of restrictions and an increase in the demand and requirement of the devices.

 

Personal Mobility Devices Market Segmentation

Grand View Research has segmented the global personal mobility devices market based on product and region:

 

Based on the Product Insights, the market is segmented into Walking Aids, Wheelchairs, Scooters.

• The wheelchair segment dominated the market for personal mobility devices and accounted for the largest revenue share of over 41.2% in 2021. The segment is expected to retain the leading position throughout the forecast period.
• Wheelchairs are one of the most common assistive devices used in personal mobility. United Nations provides appropriate legislation for requesting member states in supporting the development, production, distribution, and servicing of these mobility devices.
• The usage of appropriate wheelchairs enhances the quality of life, reduces common problems, such as deformities and pressure sores, and improves digestion and respiration.
• There are approximately 2 million new users every year, which translates to increased demand for wheelchairs in the country. Powered wheelchairs emerged as the largest sub-segment, in terms of revenue, in 2021.
• The increasing global geriatric population, chronic diseases, and growing adoption of powered wheelchairs are the key factors responsible for the growth of the wheelchair market.

 

Personal Mobility Devices Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market players are focusing on adopting various growth strategies, such as partnership and expansion of product portfolio, to retain their market position. For instance, in June 2021, Rollz international launched a new Rollz Flex 2 rollator which provides better comfort, stability, and design to the user. This rollator is among the most innovative creations of the company.

Some prominent players in the global personal mobility devices market include

• Drive DeVilbiss Healthcare
• GF Health Products, Inc.
• Invacare Corporation
• Carex Health Brands, Inc.
• Kaye Products, Inc.
• Briggs Healthcare
• Medline Industries, Inc.
• NOVA Medical Products
• Performance Health
• Rollz International

 

Order a free sample PDF of the Personal Mobility Devices Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Molecular Diagnostics Market To Boost, Based On Rising Elderly Population And Increasing Demand For Genetic Testing

 

 

 

Molecular Diagnostics Industry Overview

 

The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -1.6% from 2022 to 2030, according to a recent study by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

 

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

 

 

Molecular Diagnostics Market Segmentation

For this report, Grand View Research has segmented the global molecular diagnostics market based on product, test location, technology, application, and region:

 

Based on the Product Insights, the market is segmented into Instruments, Reagents, Others.

• The reagents segment accounted for the largest revenue share of the market in 2021.
• It is expected to maintain its dominance in upcoming years owing to its wide adoption in research and clinical settings. Standard reagents help achieve efficient and accurate results. Standardized results, improved efficiency, and cost-effectiveness are anticipated to support the market growth.
• The growing use of instruments to detect coronavirus, which was earlier developed for other infectious diseases, is anticipated to boost the market growth.

 

Based on the Test Location Insights, the market is segmented into Point-of-Care, Self-test or Over the Counter, Central Laboratories.

• Central laboratories held the largest share of the market in 2021, attributable to high procedure volumes for Covid testing in central laboratories. An increase in the number of initiatives undertaken by the government to provide various services, such as reimbursement for diagnostic tests, is another major factor anticipated to drive the market.
• There is an increasing interest in the development of molecular diagnostic platforms that can also be used in PoC settings. Therefore, various companies are designing assays & molecular diagnostic platforms for POC or near-patient testing.

 

Based on the Application Insights, the market is segmented into Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Disease, Microbiology, Others.

• The infectious disease segment accounted for the largest revenue share of the molecular diagnostics market in 2021. The increased usage of molecular, particularly PCR tests, for the diagnosis of COVID-19 is the major reason for the dominance of this segment.
• The drawbacks of traditional testing, such as long turnaround time, poor in vitro kinetic development, difficulty in growing organisms in manually prepared culture media, and the lack of sensitivity have been offset with technological advancements, such as PCR and ISH.
• Oncology segment is expected to grow at a high CAGR during the forecast period. According to WHO, in 2020, an estimated 19.3 million new cancer cases were diagnosed globally; and about 10.0 million cancer deaths occurred in 2020.

 

Based on the Technology Insights, the market is segmented into Polymerase chain reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification (TMA), Others.

• The polymerase chain reaction (PCR) segment accounted for the largest revenue share in 2021. This is attributed to its use in the detection of COVID-19 and other infectious diseases. The increasing use of high-throughput PCR technology to detect infectious diseases and genetic diseases is expected to drive market growth.
• Sequencing technologies for the molecular diagnostics market include DNA sequencing processes and emerging NGS technologies, such as sequencing platforms and RNA sequencing.
• DNA sequencing technologies are integrally linked to drug discovery, novel drug development, and personalized medicine. Companies are launching new NGS-based tests for early disease diagnosis.
• The sequence specificity of the ISH technique is a major application that helps in understanding pathogenic processes and performing molecular testing for diagnosis, monitoring, and treatment of cancer. Key applications of ISH technology include identifying and investigating mRNA expression in preserved tissue samples, using probes that are complementary to the concerned sequence, and molecular diagnosis of chromosomal integrity using Fluorescence ISH (FISH).

 

Molecular Diagnostics Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Players such as Roche are using mergers and acquisitions strategy to enhance product capabilities and promote their product offerings. For instance, in May 2021, Roche acquired GenMark Diagnostics for USD 1.8 billion. This acquisition will help Roche expand its molecular diagnostics portfolio.

Some prominent players in the global molecular diagnostics market include

• BD
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Abbott
• Agilent Technologies, Inc.
• Danaher
• Hologic Inc. (Gen Probe)
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• Grifols, S.A.
• QIAGEN
• F. Hoffmann-La Roche, Ltd.
• Siemens Healthineers AG
• Sysmex Corporation

 

Order a free sample PDF of the Molecular Diagnostics Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Radiation Oncology Market To Forsee Commendable Growth, Due To Rising Adoption Of Radiotherapy In Cancer Treatment

 

 

Radiation Oncology Industry Overview

 

The global radiation oncology market size is expected to reach USD 11.7 billion by 2028, registering a CAGR of 7.0% over the forecast period, according to a new report by Grand View Research, Inc. The rising incidence of cancer and technological advancement in radiation therapy equipment are some of the major factors driving the growth of the market.

 

There have been various technological advancements in radiotherapy equipment over the last decade, which has been a major factor for growth. Advancement from 2D to 3D conformal radiotherapy, motion tracking, and real-time imaging has helped improve radiation targeting and thereby reduce exposure to the surrounding healthy tissues. For instance, Accuray Incorporated introduced its motion monitoring and correction tools, Synchrony, for the Radixact device in April 2019. In contrast to traditional radiotherapy devices, this technology increases dosage accuracy and treatment times and is comparatively more effective.

 

Radiation Oncology Market Segmentation

Grand View Research has segmented the global radiation oncology market on the basis of type, technology, application, and region:

 

Based on the Type Insights, the market is segmented into EBRT, Proton Therapy, Internal Beam Radiation Therapy.

• The External Beam Radiation Therapy (EBRT) segment dominated the market for radiation oncology and accounted for the largest revenue share of 79.3% in 2020 owing to the relatively higher price of equipment and high installed base of external beam radiation therapy equipment. EBRT is the most widely used form of radiotherapy.
• Compact advanced radiotherapy systems such as Gamma Knife, Cyber Knife, and tomotherapy have a wide range of applications. Gamma Knife is commonly used for the treatment of brain tumors. It utilizes high-intensity cobalt radiation that concentrates radiation in small volumes.
• Brachytherapy is likely to gain a significant share in the market for radiation oncology during the forecast period, owing to factors such as decreased length of hospital stay, and faster recovery. Also, the development and approval of new brachytherapy devices for the treatment of various cancers is anticipated to boost the segment growth.

 

Based on the Technology Insights, the market is segmented into EBRT, Brachytherapy.

• The IMRT technology segment dominated the market for radiation oncology and accounted for the largest revenue share of 25.0% in 2020.
• IMRT allows a change in radiation intensity during treatment to specifically target cancer cells and limit the damage to adjoining healthy tissues. Linear accelerators are used to deliver a radiation dose to the exact dimensions of tumors.
• In July 2019, Swiss Medical Network purchased a Radixact system, an Image-guided, Intensity-modulated Radiation Therapy (IG-IMRT), developed by Accuray, Inc. to provide a highly precise radiation system to treat patients.

 

Based on the Application Insights, the market is segmented into EBRT, Internal Beam Radiation Therapy.

• The EBRT segment dominated the radiation oncology market and accounted for the largest revenue share of 79.0% in 2020. Breast cancer treated using EBRT accounted for a significant share in 2020 due to high effectiveness and supporting awareness programs.
• According to the International Agency for Research on Cancer, the incidence of lung cancer is expected to grow from 2.21 million in 2020 to 2.9 million by 2030. Radiation therapy is used for the treatment of both NSCLC and SCLC, either along with chemotherapy or post-surgery or pre-surgery.
• Brachytherapy is used for the treatment of gynecological, breast, lung, penile, and other types of cancer. IBRT for the treatment of prostate cancer accounted for the maximum share in 2020.

 

Radiation Oncology Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The key companies are adopting strategies such as mergers and acquisitions and partnerships, to acquire a larger market share, globally. In August 2020, Siemens Healthcare GmbH announced its plans to acquire Varian Medical Systems, Inc. for USD 16.4 billion. The deal is expected to be completed by H1 2020.

Some prominent players in the global radiation oncology market include

• Varian Medical Systems, Inc.
• Elekta AB
• Accuray Incorporated
• Ion Beam Applications (IBA)
• R. BARD, INC. (BD)
• Isoray Medical
• Mevion Medical Systems, Inc.
• Nordion Inc.
• NTP Radioisotopes SOC Ltd.
• Curium Pharma
• Viewray Technologies, Inc.

 

Order a free sample PDF of the Radiation Oncology Market Intelligence Study, published by Grand View Research.

Clinical Decision Support Systems Market To Create Business Opportunities, Owing To Integrated Reliable Technical Solutions

 

 

 

 

The global clinical decision support systems market size is expected to reach USD 10.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.4% from 2022 to 2030. Surging demand for quality care is one of the primary factors augmenting the market growth. Constant lookout for reliable technology solutions by care providers is also expected to work in favor of the market. The growing interest in enhanced medical care and efficient decision-making is projected to fuel the adoption of CDSS and EHR.

 

Clinical Decision Support Systems Market Segmentation

Grand View Research has segmented the global clinical decision support systems market based on product, application, delivery mode, component, and region:

 

Based on the Product Insights, the market is segmented into Standalone CDSS, Integrated CPOE with CDSS, Integrated E.H.R. with CDSS, Integrated CDSS with CPOE & E.H.R..

• Standalone CDSS held the largest revenue share of over 30.0% in 2021 as it is widely adopted due to its low cost and simplicity. Ease to use in hospitals and clinical settings has contributed to its growth. The standalone segment will continue to dominate the market throughout the forecast period.
• The integrated EHR with CDSS segment is anticipated to witness lucrative growth over the forecast period. Increasing awareness and adoption of electronic health records (EHR) by multi-specialty health care units is poised to influence the growth of the integrated EHR with the CDSS segment.
• CDSS and EHRs are often integrated to streamline workflows and make use of present data sets. There is an increasing number of CDSS functions that are built into EHR systems, which is expected to support segment growth.

 

Based on the Application Insights, the market is segmented into Drug-drug Interactions, Drug Allergy Alerts, Clinical Reminders, Clinical Guidelines, Drug Dosing Support, Others.

• Drug allergy alerts held the largest revenue share of over 25.0% in 2021. Several people have allergies to some specific drugs, and consequently, it is important to have systems that provide allergy alerts. The burden of allergies, i.e., drug allergies, is rising.
• In the process of prescribing, dispensing, or administering a drug, a medicine error may happen and can have adverse significance, e.g., medication may be given to a patient with a documented allergy to that drug.
• The clinical guidelines segment is anticipated to witness lucrative growth over the forecast period. The CDS system offers guidelines for treatment and diagnosis.

 

Based on the Component Insights, the market is segmented into Hardware, Software, Services.

• The services segment held the largest revenue share of over 40.0% in 2021. This is due to timely up-gradation of software as well as the knowledge base available for use. Services in CDSS involve the maintenance of components and their accessories.
• The software segment is anticipated to witness lucrative growth over the forecast period. The CDSS software, when used in integration with software for CPOE and EHRs, provides enhanced decision support by making customized and specific results for the particular patient.

 

Based on the Delivery Mode Insights, the market is segmented into Web-based Systems, Cloud-based Systems, On-premise Systems.

• The on-premise systems segment captured the largest revenue share of over 40.0% in 2021. Cloud-based systems held the second-largest revenue share in 2021 owing to significant innovation in information technology, with potential applications in the healthcare sector.
• The primary services provided under cloud computing are Platform as a Service (PaaS) which creates a platform, i.e., develops an OS to run the software, Infrastructure as a Service (IaaS) which uses virtual technology to create a user interface to provide the services, and Software as a Service (SaaS) which forms the most critical aspect of the cloud provider as it enables them to operate, install, and manage software to provide services to the end user.
• CDSSs require access to healthcare data and knowledge, which is stored in a database. Data stored on the web is easily accessible through mobile and computer devices. Web-based devices use the data stored on the web to provide decision support to medical practitioners.

 

Clinical Decision Support Systems Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market is fairly competitive. The market has been characterized by the presence of most notable participants, along with other providers of clinical decision support systems. These players are involved in new product launches, product innovations, acquisitions, and partnerships to gain a competitive edge over each other.

 

Some prominent players in the global clinical decision support systems market include

• McKesson Corporation
• Cerner Corporation
• Siemens Healthineers GmbH
• Allscripts Healthcare, LLC
• athenahealth, Inc.
• NextGen Healthcare Inc.
• Koninklijke Philips N.V. (Royal Philips)
• IBM Corporation
• Agfa-Gevaert Group
• Wolters Kluwer N.V.

 

Order a free sample PDF of the Clinical Decision Support Systems Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Antiseptics And Disinfectants Market To Create Business Opportunities, Based On Increasing Prevalence Of Diseases Due To Lack Of Home Cleanliness

 

 

 

 

Antiseptics And Disinfectants Industry Overview

 

The global antiseptics and disinfectants market size is anticipated to reach USD 63.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.1% from 2022 to 2030. Key factors driving the market expansion include technological advancements in antiseptics and disinfectants along with increasing use of endoscope reprocessors and surgical units. The current COVID-19 outbreak is expected to have a substantial impact on the market. The pandemic has resulted in a significant surge in demand for emergency supplies, hospital equipment, medicines, and medical disposables. According to Eurostat in 2020, extra-EU exports and imports of COVID-19 related products increased by 5.5 % and 10.4 % respectively, compared to 2019.

 

Antiseptics And Disinfectants Market Segmentation

Grand View Research has segmented the global antiseptics and disinfectants market on the basis of type, product, sales channel, end-use, and region:

 

Based on the Type Insights, the market is segmented into Quaternary Ammonium Compounds, Chlorine Compounds, Alcohols & Aldehyde Products, Enzyme, Others.

• The quaternary ammonium compounds segment held the largest revenue share of 31.4% in 2021 and is expected to witness considerable growth over the forecast period.
• Quaternary ammonium compounds are widely used as surface disinfectants in hospitals and laboratories. These compounds aid in controlling the spread of healthcare-associated infections in hospitals and clinics.
• The rising incidence of hospital-acquired infections across the globe is likely to positively impact the segment growth. For instance, as per WHO, every year, 7 out of every 100 hospitalized patients in industrialized nations and 10 out of every 100 hospitalized patients in underdeveloped countries acquire at least one healthcare-associated infection.
• The enzyme segment is anticipated to witness the fastest growth rate over the forecast period. Generally, enzyme-based antiseptics and disinfectants are used to control odors that are created by chemical processes.
• The demand for these items is predicted to rise as the number of research facilities grows as a result of increased R&D spending around the world.

 

Based on the Product Insights, the market is segmented into Enzymatic Cleaners, Medical Device Disinfectants, Surface Disinfectants.

• The medical device disinfectants segment held the largest revenue share of 45.7% in 2021. Medical device disinfectants are generally used for reprocessing surgical units and endoscopes.
• Glutaraldehyde, phenol/phenate, hydrogen peroxide, and peracetic acid are some of the disinfectants used for reprocessing/disinfection of medical devices. Proper reprocessing of medical devices and endoscopes is essential as they transmit infection from one patient to another due to direct contact with skin.
• The enzymatic cleaners segment is anticipated to witness the fastest growth rate over the forecast period. Enzymatic cleaners are more efficient on bacterial surfaces and are commonly used to avoid odor. It's commonly used to disinfect testing kits and surgical equipment in clinics and hospitals. 

 

Based on the Sales Channel Insights, the market is segmented into B2B, FMCG.

• The B2B segment dominated the market for antiseptics and disinfectants and held the largest revenue share of 65.1% in 2021. 
• B2B sales channels usually have longer sales cycles and higher-order values. B2B sales channel is expected to witness a low growth rate during the forecast period owing to entry barriers in the B2B business, which include a lack of investment to develop technologically advanced products and challenges pertaining to coordinating with various vendors.
• Medical device disinfectants, enzymatic cleaners, and surface disinfectants are major antiseptics and disinfectants marketed under the B2B sales channel. Hospitals, clinics, healthcare providers, and suppliers are major end-users of the B2B sales channel.
• The FMCG distribution channel comprises three major entities: agents, facilitators, and merchants. Agents generally generate sales by promoting the products of the company. Agents can be a member of the company or independent individuals.
• Facilitators are generally involved in the transportation of manufactured goods from one place to another. Warehouse owners, logistic services, and independent types are included under the facilitator’s category. Wholesalers and retailers are generally categorized under the merchant’s category. Consumers generally purchase FMCG products directly from retailers and wholesalers.

 

Based on the End-use Insights, the market is segmented into Hospitals, Clinics, Others.

• The hospital segment dominated the market for antiseptics and disinfectants and accounted for a revenue share of 46.2% in 2021. The increasing incidence of hospital-acquired infections across the globe is one of the major reasons for segment growth over the forecast period.
• For instance, as per Eurostat, Germany, and France, had the highest healthcare expenditure (around 11.8%) in GDP in 2019. Thus, such factors are expected to propel segment growth over the forecast period.
• The increasing number of surgical procedures and hospitals will be important drivers of the segment's growth. To maintain a healthy atmosphere in the clinic, basic sanitation and hygiene are required.

 

Antiseptics And Disinfectants Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Key players are involved in adopting strategies such as mergers and acquisitions, partnerships, and launching new products to strengthen their foothold in the market for antiseptics and disinfectants. Key players are entering into mergers and acquisitions to increase their market share and customer base across the globe.

Some prominent players in the global antiseptics and disinfectants market include

• 3M
• Reckitt Benckiser
• Steris Plc
• Kimberly-Clark Corporation
• Bio-Cide International, Inc.
• Cardinal Health
• BD
• Johnson & Johnson

 

Order a free sample PDF of the Antiseptics And Disinfectants Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Pulse Oximeter Market To Predict Global Expansion, As Of Increasing Adoption Of Pulse Oximetry Devices Till 2028

 

 

 

Pulse Oximeter Industry Overview

 

The global pulse oximeter market size is expected to reach USD 3.4 billion by 2028, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028. Technological advancements in products, growing healthcare costs, and readmission, and increasing adoption of pulse oximetry devices are expected to boost market growth during the forecast period. Market players are introducing devices that are more efficient and support telehealth approaches. For instance, in February 2017, the company received a CE mark for Rad-97 Pulse CO-Oximeter used to monitor blood pressure at set intervals. It is also capable of transferring the data to a remotely connected device.

 

Pulse Oximeter Market Segmentation

Grand View Research has segmented the global pulse oximeter market on the basis of type, end-use, and region:

 

Based on the Type Insights, the market is segmented into Fingertip, Handheld, Others.

• The handheld segment dominated the market for the pulse oximeter and accounted for the largest revenue share of 38.9% in 2020.
• The market is primarily driven by the fact that these oximeters are easy to use in case of emergencies. The oxygen saturation level of a patient can strongly influence the course of treatment. A rise in the number of stroke cases and surgeries is anticipated to boost market growth over the forecast period.
• Technological advancements in oximeters are expected to drive the segment. Added features such as easy transfer of data, extensive memory, alarm system, and Bluetooth increase the efficiency of products. 
• The COVID-19 pandemic has restricted the visits to medical facilities hindering medical care services, and manufacturers are innovating products to provide alternative telehealth
• In January 2021, Tyto Care, a telehealth company launched a fingertip pulse oximeter that connects to the Tyto Care device via a cable to logging test results to patients EHR enabling its remote monitoring by clinicians.

 

Based on the End-use Insights, the market is segmented into Hospitals & Other Healthcare Facilities, Homecare.

• The hospitals and other healthcare facilities segment dominated the pulse oximeter market and accounted for the largest revenue share of 82.0% in 2020 due to an increase in the number of surgeries and emergency room visits.
• Long-term care facilities are at high risk of COVID-19 infections, and residents are being continuously monitored for symptoms by checking vital respiratory parameters. Thus, demand for pulse oximeters from home healthcare centers and long-term care facilities is expected to increase during the COVID-19 pandemic.
• The homecare segment is expected to witness lucrative growth during the forecast period due to factors such as increasing awareness regarding the importance of monitoring oxygen levels. Fingertip pulse oximeters are considered affordable and effective in homecare, as they can help track and store a patient’s oxygen level readings, which can help reduce the risk of readmission to a hospital.

 

Pulse Oximeter Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market is fragmented with the presence of various global and regional manufacturers. The market is expected to adopt various strategies such as product launches and acquisitions by key players to expand their market share.

 

Some prominent players in the global pulse oximeter market include

• Medtronic (Covidien)
• Carefusion Corp.
• GE Healthcare
• Philips Healthcare
• Masimo
• CAS Medical Systems, Inc.
• Opto Circuits India Ltd.
• Nonin Medical, Inc.
• Smiths Medical
• Welch Allyn
• Spacelabs Healthcare
• Meditech Equipment Co.
• Nihon Kohden Corporation

 

Order a free sample PDF of the Pulse Oximeter Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.